Zai Lab Limited (NASDAQ:ZLAB – Get Free Report) insider Harald Reinhart sold 7,431 shares of the business’s stock in a transaction that occurred on Wednesday, June 26th. The stock was sold at an average price of $17.90, for a total value of $133,014.90. Following the sale, the insider now directly owns 62,619 shares in the company, valued at $1,120,880.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Zai Lab Stock Performance
Zai Lab stock opened at $17.33 on Friday. The business has a fifty day moving average of $18.36 and a two-hundred day moving average of $20.19. Zai Lab Limited has a twelve month low of $13.48 and a twelve month high of $32.60.
Zai Lab (NASDAQ:ZLAB – Get Free Report) last posted its earnings results on Wednesday, May 8th. The company reported ($0.55) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.93) by $0.38. The company had revenue of $87.15 million during the quarter, compared to analyst estimates of $77.07 million. Zai Lab had a negative return on equity of 40.21% and a negative net margin of 116.45%. During the same quarter in the prior year, the business earned ($0.51) earnings per share. On average, equities analysts forecast that Zai Lab Limited will post -2.78 EPS for the current fiscal year.
Hedge Funds Weigh In On Zai Lab
Wall Street Analyst Weigh In
Separately, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zai Lab in a research note on Tuesday. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $64.57.
Read Our Latest Stock Analysis on Zai Lab
About Zai Lab
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.
Further Reading
- Five stocks we like better than Zai Lab
- Investing in Construction Stocks
- Qualcomm Stock: AI-Powered Growth Despite Volatility
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Salesforce Stock: Meeting Recap, AI Focus, and Forecast
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Is CAVA Overextended? A Closer Look at This High-Flying Stock
Receive News & Ratings for Zai Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab and related companies with MarketBeat.com's FREE daily email newsletter.